Listed

Nanoviricides, Inc.: Form 10-K for the period ended Jun 30, 2022

Filed with the SEC on Oct 13, 2022 and accepted by EDGAR at Oct 13, 2022, 21:12 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2021-07-01 to 2022-06-30$5.8mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-07-01 to 2022-06-30−$8.1mus-gaap:OperatingIncomeLoss
Interest expense12 months2021-07-01 to 2022-06-30$5.1kus-gaap:InterestExpense
Net income12 months2021-07-01 to 2022-06-30−$8.1mus-gaap:NetIncomeLoss
Diluted EPS12 months2021-07-01 to 2022-06-30−$0.70us-gaap:EarningsPerShareDiluted
Basic EPS12 months2021-07-01 to 2022-06-30−$0.70us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2021-07-01 to 2022-06-3011,534,698 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-07-01 to 2022-06-30−$5.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-07-01 to 2022-06-30$324.3kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-06-30$14.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-06-30$14.4mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$23.5mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$412.8kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2022-06-30$23.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-22-002878. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.